Galectin Therapeutics Inc Total Liabilities
Galectin Therapeutics Inc total liabilities. Based on the latest financial reports, Galectin Therapeutics Inc (GALT) has total liabilities worth $146.00 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Galectin Therapeutics Inc (GALT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Galectin Therapeutics Inc (2000–2025)
Total liabilities of Galectin Therapeutics Inc from 2000 to 2025. This chart illustrates how Galectin Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore GALT long-term investments to assets to see how much of total assets are deployed in long-term investments.
Galectin Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Galectin Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dalian Zhiyun Automation Co Ltd
SHE:300097
|
China | CN¥432.54 Million |
|
National Fertilizers Limited
NSE:NFL
|
India | Rs88.83 Billion |
|
Pondy Oxides & Chemicals Limited
NSE:POCL
|
India | Rs-7.88 Billion |
|
Career Technology MFG Co Ltd
TW:6153
|
Taiwan | NT$6.91 Billion |
|
Lootom Telcovideo Network Wuxi Co Ltd
SHE:300555
|
China | CN¥66.67 Million |
|
Guangdong Fangyuan Environment Co. Ltd. A
SHG:688148
|
China | CN¥2.43 Billion |
|
BLD Plantation Bhd
KLSE:5069
|
Malaysia | RM477.97 Million |
|
Regional Management Corp
NYSE:RM
|
USA | $1.70 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Galectin Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Galectin Therapeutics Inc total assets.
Liquidity & Leverage Metrics
Galectin Therapeutics Inc Total Liabilities Ratios Explained
Galectin Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 9.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galectin Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galectin Therapeutics Inc (2000–2025)
The table below shows the annual total liabilities of Galectin Therapeutics Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $145.73 Million | +20.87% |
| 2024-12-31 | $120.56 Million | +36.32% |
| 2023-12-31 | $88.44 Million | +65.38% |
| 2022-12-31 | $53.48 Million | +36.39% |
| 2021-12-31 | $39.21 Million | +625.19% |
| 2020-12-31 | $5.41 Million | +88.27% |
| 2019-12-31 | $2.87 Million | +36.24% |
| 2018-12-31 | $2.11 Million | -28.98% |
| 2017-12-31 | $2.97 Million | -21.48% |
| 2016-12-31 | $3.78 Million | +177.94% |
| 2015-12-31 | $1.36 Million | -20.14% |
| 2014-12-31 | $1.70 Million | -31.50% |
| 2013-12-31 | $2.49 Million | +51.22% |
| 2012-12-31 | $1.64 Million | -25.78% |
| 2011-12-31 | $2.21 Million | -72.29% |
| 2010-12-31 | $7.99 Million | +63.04% |
| 2009-12-31 | $4.90 Million | +317.99% |
| 2008-12-31 | $1.17 Million | -75.07% |
| 2007-12-31 | $4.71 Million | -26.30% |
| 2006-12-31 | $6.38 Million | +362.68% |
| 2005-12-31 | $1.38 Million | +37.31% |
| 2004-12-31 | $1.00 Million | +165.94% |
| 2003-12-31 | $377.91K | -43.32% |
| 2002-12-31 | $666.79K | +21.08% |
| 2001-12-31 | $550.70K | +205.95% |
| 2000-12-31 | $180.00K | -- |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhos… Read more